Biofrontera AG (B8F) - Financial and Strategic SWOT Analysis Review
June 2019
48
About the Report
About the Report
Biofrontera AG (B8F) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company's businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company's key strengths and weaknesses and the potential opportunities and threats. The profile helps you formulate strategies that augment your business by enabling you to understand your partners, customers and competitors better.
The profile contains critical company information including:
- Business description - A detailed description of the company's operations and business divisions.
- Corporate strategy - Analyst's summarization of the company's business strategy.
- SWOT Analysis - A detailed analysis of the company's strengths, weakness, opportunities and threats.
- Company history - Progression of key events associated with the company.
- Major products and services - A list of major products, services and brands of the company.
- Key competitors - A list of key competitors to the company.
- Key employees - A list of the key executives of the company.
- Executive biographies - A brief summary of the executives' employment history.
- Key operational heads - A list of personnel heading key departments/functions.
- Important locations and subsidiaries - A list and contact details of key locations and subsidiaries of the company.
- Key manufacturing facilities - A list of key manufacturing facilities of the company.
- Detailed financial ratios for the past five years - The latest financial ratios derived from the annual financial statements published by the company with 5 years history.
- Interim ratios for the last five interim periods - The latest financial ratios derived from the quarterly/semi-annual financial statements published by the company for 5 interims history.
Highlights
Biofrontera AG (Biofrontera) is a biopharmaceutical company that develops and markets dermatological medications and medical cosmetics. The company's products comprise Ameluz, BF-RhodoLED and Belixos. Its prescription drug Ameluz is used for the treatment of skin disease actinic keratosis. Biofrontera's BF-RhodoLED is a lamp used for photodynamic therapy with LEDs emitting red light. Belixos is a cosmetic product,indicated for regenerative care of reddened and inflamed skin. Its Belixos line of products include Belixos creme, Belixos liquid, Belixos gel, Belixos to go and Belixos protect. The company sells products to wholesalers, physicians, clinics and licensing partners. Biofrontera is headquartered in Leverkusen, Germany.
Biofrontera AG Key Recent Developments
Jun 04,2019: Biofrontera nominates new candidate for the Supervisory Board
Apr 29,2019: Biofrontera reports full year 2018 financial results
Apr 29,2019: Biofrontera reports first quarter 2019 financial results
Apr 15,2019: Biofrontera reports preliminary unaudited sales revenue for the first three months of 2019
Mar 27,2019: Biofrontera: Changes in the composition of the Supervisory Board
Key benefits of buying this profile include:
You get detailed information about the company and its operations to identify potential customers and suppliers.
- The profile analyzes the company's business structure, operations, major products and services, prospects, locations and subsidiaries, key executives and their biographies and key competitors.
Understand and respond to your competitors' business structure and strategies, and capitalize on their weaknesses. Stay up to date on the major developments affecting the company.
- The company's core strengths and weaknesses and areas of development or decline are analyzed and presented in the profile objectively. Recent developments in the company covered in the profile help you track important events.
Equip yourself with information that enables you to sharpen your strategies and transform your operations profitably.
- Opportunities that the company can explore and exploit are sized up and its growth potential assessed in the profile. Competitive and/or technological threats are highlighted.
Scout for potential investments and acquisition targets, with detailed insight into the companies' strategic, financial and operational performance.
- Financial ratio presented for major public companies in the profile include the revenue trends, profitability, growth, margins and returns, liquidity and leverage, financial position and efficiency ratios.
Gain key insights into the company for academic or business research.
- Key elements such as SWOT analysis, corporate strategy and financial ratios and charts are incorporated in the profile to assist your academic or business research needs.
Note: Some sections may be missing if data is unavailable for the company
Products
Products
Biofrontera AG, SWOT analysis, SWOT, Strengths, Weaknesses, Opportunities, Threats, Corporate Strategy, Key Ratios, Share Data, Performance, Financial Performance, Overview, Business Description, Major Product, Brands, History,Key Employees, Key Operational Heads, Strategy, Key Competitors, Company Statement, Capital Market Ratios, Financial Ratios, Annual Ratios, Interim Ratios, Ratio Charts
Companies
MIKA Pharma GmbH
Intendis GmbH
Galderma SA
Almirall Hermal GmbH
Table of Contents
Table of Contents
Table of Contents
Table of Contents
List of Tables
List of Figures
Section 1 - About the Company
Biofrontera AG - Key Facts
Biofrontera AG - Key Employees
Biofrontera AG - Key Employee Biographies
Biofrontera AG - Major Products and Services
Biofrontera AG - History
Biofrontera AG - Company Statement
Biofrontera AG - Locations And Subsidiaries
Head Office
Other Locations & Subsidiaries
Section 2 - Company Analysis
Company Overview
Biofrontera AG - Business Description
R&D Overview
Biofrontera AG - Corporate Strategy
Biofrontera AG - SWOT Analysis
SWOT Analysis - Overview
Biofrontera AG - Strengths
Biofrontera AG - Weaknesses
Biofrontera AG - Opportunities
Biofrontera AG - Threats
Biofrontera AG - Key Competitors
Section 3 - Company Financial Ratios
Financial Ratios - Capital Market Ratios
Financial Ratios - Annual Ratios
Performance Chart
Financial Performance
Financial Ratios - Interim Ratios
Financial Ratios - Ratio Charts
Section 4 - Company's Lifesciences Financial Deals and Alliances
Biofrontera AG, Pharmaceuticals & Healthcare, Deals By Year, 2013 to YTD 2019
Biofrontera AG, Pharmaceuticals & Healthcare, Deals By Type, 2013 to YTD 2019
Biofrontera AG, Recent Deals Summary
Section 5 - Company's Recent Developments
Jun 04, 2019: Biofrontera nominates new candidate for the Supervisory Board
Apr 29, 2019: Biofrontera reports full year 2018 financial results
Apr 29, 2019: Biofrontera reports first quarter 2019 financial results
Apr 15, 2019: Biofrontera reports preliminary unaudited sales revenue for the first three months of 2019
Mar 27, 2019: Biofrontera: Changes in the composition of the Supervisory Board
Mar 25, 2019: Biofrontera provides corporate update; conference call details
Feb 25, 2019: Biofrontera Honored with Prestigious Silver Stevie Award for Outstanding U.S. Customer Service Department of the Year
Feb 11, 2019: Biofrontera implements new Falsified Medicines Directive
Jan 22, 2019: Biofrontera announces preliminary unaudited sales revenue and updates consolidated net income guidance for the full year 2018
Dec 27, 2018: Biofrontera: Ruling by the U.S. District Court of Massachussetts
Section 6 - Appendix
Methodology
Ratio Definitions
About GlobalData
Contact Us
Disclaimer
List of Figure
List of Figures
Biofrontera AG, Performance Chart (2014 - 2018)
Biofrontera AG, Ratio Charts
Biofrontera AG, Pharmaceuticals & Healthcare, Deals By Year, 2013 to YTD 2019
Biofrontera AG, Pharmaceuticals & Healthcare, Deals by Type, 2013 to YTD 2019
List of Table
List of Tables
Biofrontera AG, Key Facts
Biofrontera AG, Key Employees
Biofrontera AG, Key Employee Biographies
Biofrontera AG, Major Products and Services
Biofrontera AG, History
Biofrontera AG, Subsidiaries
Biofrontera AG, Key Competitors
Biofrontera AG, Ratios based on current share price
Biofrontera AG, Annual Ratios
Biofrontera AG, Annual Ratios (Cont...1)
Biofrontera AG, Interim Ratios
Biofrontera AG, Pharmaceuticals & Healthcare, Deals By Year, 2013 to YTD 2019
Biofrontera AG, Pharmaceuticals & Healthcare, Deals By Type, 2013 to YTD 2019
Biofrontera AG, Recent Deals Summary
Currency Codes
Capital Market Ratios
Equity Ratios
Profitability Ratios
Cost Ratios
Liquidity Ratios
Leverage Ratios
Efficiency Ratios
Why Buy From US?
What makes us stand out is that our consultants follows Robust, Refine and Result (RRR) methodology. i.e. Robust for clear definitions, approaches and sanity checking, Refine for differentiating respondents facts and opinions and Result for presenting data with story
We have set a benchmark in the industry by offering our clients with syndicated and customized market research reports featuring coverage of entire market as well as meticulous research and analyst insights.
While we don't replace traditional research, we flip the method upside down. Our dual approach of Top Bottom & Bottom Top ensures quality deliverable by not just verifying company fundamentals but also looking at the sector and macroeconomic factors.
With one step in the future, our research team constantly tries to show you the bigger picture. We help with some of the tough questions you may encounter along the way: How is the industry positioned? Best marketing channel? KPI's of competitors? By aligning every element, we help maximize success.
Our report gives you instant access to the answers and sources that other companies might choose to hide. We elaborate each steps of research methodology we have used and showcase you the sample size to earn your trust.
If you need any support, we are here! We pride ourselves on universe strength, data quality, and quick, friendly, and professional service.